Authorised Indian Distributor
Saxsons Group
New Delhi, India · Since 1997
Iodine-131 Therapy CapsuleRadioiodine Therapy
High-activity I-131 capsules for thyroid cancer ablation, remnant ablation after thyroidectomy, and hyperthyroidism therapy. Available in calibrated activity levels per prescription, AERB licensed for Indian hospitals.
Key Features
- High-activity I-131 capsules for thyroid cancer ablation
- Available in calibrated activity levels per prescription
- Gelatine capsule form — easy oral administration
- Certificate of Analysis with each batch — activity verification
- Shipped in lead-shielded transport container — radiation safety compliant
All Features
- High-activity I-131 capsules for thyroid cancer ablation
- Available in calibrated activity levels per prescription
- Gelatine capsule form — easy oral administration
- Certificate of Analysis with each batch — activity verification
- Shipped in lead-shielded transport container — radiation safety compliant
- AERB-licensed supply chain for Indian therapeutic nuclear medicine
- Activity calibrated to specified date and time of administration
- Compatible with standard thyroid ablation protocols
- Suitable for Graves' disease and toxic adenoma hyperthyroidism therapy
- Dosimetric activity planning support available from Saxsons team
- Suitable for outpatient (low dose) and inpatient (high dose) therapy protocols
- Full regulatory documentation for hospital pharmacy and AERB records
Technical Specifications
| Radionuclide | Iodine-131 (I-131) |
| Physical form | Oral gelatine capsule |
| Half-life | 8.02 days |
| Decay emissions | β⁻ (max 606 keV, 89%); γ 364 keV (82%) |
| Activity range | Prescription-specific; low (370 MBq) to high (7,400 MBq+) |
| Radiochemical form | Sodium iodide (NaI) in gelatin capsule |
| Radiochemical purity | ≥ 99% iodide form |
| Calibration | Activity stated at a defined reference date/time |
| Shielding | Lead pot and outer transport container per IAEA regulations |
| Stability | 14 days from calibration date (stored as directed) |
| Clinical use | Thyroid cancer ablation, remnant ablation, hyperthyroidism |
| AERB status | Licensed supply; hospital AERB authorisation required |
Applications
Radioiodine — the gold standard for thyroid disease management
Post-thyroidectomy Ablation
Destruction of residual thyroid tissue after total thyroidectomy for differentiated thyroid cancer. Standard ablation doses 1,110–3,700 MBq depending on risk stratification.
Metastatic Thyroid Cancer
High-dose I-131 therapy for loco-regional lymph node metastases and distant metastases in differentiated (papillary and follicular) thyroid carcinoma.
Hyperthyroidism — Graves'
Definitive treatment for Graves' disease with calculated or fixed-activity radioiodine dose. Long-term remission with single treatment in the majority of patients.
Toxic Multinodular Goitre
I-131 therapy for autonomous functioning thyroid nodules and toxic multinodular goitre. Reduces goitre volume and normalises thyroid function.
Remnant Ablation Monitoring
Post-ablation whole-body I-131 scanning using the therapeutic dose emission. Documents complete ablation and detects occult metastatic disease.
Outpatient Low-Dose Therapy
Low-activity I-131 (< 600 MBq) for outpatient hyperthyroidism treatment where radiation protection criteria permit discharge on day of administration.
Why Iodine-131 Therapy Capsule?
Each capsule is calibrated to the exact activity and reference time requested. Your nuclear medicine physician prescribes; the capsule arrives ready for administration — no in-house dispensing or dilution required.
I-131's β-particle (606 keV max) treats locally while the 364 keV gamma enables post-therapy whole-body scintigraphy. One radionuclide serves both the therapeutic and the imaging purpose in thyroid cancer follow-up.
Saxsons holds the required AERB import licence for I-131 therapeutic supply. Full batch documentation, transport safety data and patient administration records are provided with every order.
I-131 Therapy
More for this product
Each card opens a focused post for a specific specialty — peer-reviewed evidence and clinical workflow, written for the persona you select.
FAQ
I-131 therapy supply — questions we hear from Indian nuclear-medicine teams
What I-131 treats and why thyroid tissue takes it up, why activity has to be scheduled against therapy dates, which supply forms fit which indication, and how the therapy sits inside the AERB isolation-room framework.
Q.What clinical problem does I-131 therapy solve?
I-131 (iodine-131) is a beta + gamma emitter that thyroid tissue avidly concentrates because iodine is the natural substrate for thyroid hormone synthesis. That property makes I-131 the definitive therapy for hyperthyroidism (Graves' disease, toxic nodular goitre), for post-thyroidectomy remnant ablation in differentiated thyroid cancer, and for treatment of iodine-avid metastatic thyroid cancer. The beta particle delivers the therapeutic dose to the thyroid tissue; the gamma photon lets the technologist image the uptake to confirm targeting.
Q.Why does I-131 need a specific supply chain rather than being made on-site?
I-131 has an 8-day half-life — long enough to import as a finished patient-ready capsule or oral solution, too short to stockpile. Every therapy dose is ordered against a specific patient administration date; the activity has to arrive with enough half-lives of headroom to still deliver the prescribed dose on the treatment morning. Saxsons coordinates the weekly production window at the parent nuclide facility against the department's scheduled therapy list so the activity lands on the day it is needed.
Q.What forms does the I-131 come in?
Two supply forms: pre-measured therapy capsules (for hyperthyroidism ablation and remnant ablation — the patient swallows the capsule; less risk of contamination on the ward) and oral solution (for high-activity metastatic-thyroid-cancer therapy where the specific activity of a capsule would be constraining). The department orders the form matched to the indication and prescribed activity.
Q.What AERB and radiation-safety framework does I-131 therapy sit inside?
I-131 therapy is governed by the AERB Safety Code for Nuclear Medicine Facility — patient-isolation-room shielding, waste-hold protocols for excreta (I-131 decays to background in ~10 half-lives / 80 days), staff dose monitoring during administration, and post-discharge instructions to the patient family. The department dossier includes room shielding calculations against the maximum I-131 activity handled per session and Bio-Medical Waste Management Rules records for the isolation-room bed linen chain.
Q.How is I-131 supplied and supported in India?
Distributed across India by Saxsons Group with cold-chain logistics against scheduled therapy dates, receiving documentation for the AERB dossier, per-dose calibration certification and clinical-support workflow for the isolation-room administration. Saxsons has coordinated I-131 supply for Indian NM departments for 40+ years.
Iodine-131 Therapy Capsule supplier in India — Saxsons Group
Saxsons Group has supplied nuclear medicine equipment to over 1,000 Indian hospitals since 1988. Every consignment of Iodine-131 Therapy Capsule ships with cold-chain logistics, AERB import documentation, CDSCO registration references and a Certificate of Analysis delivered before dispatch — the paperwork your radiation-safety and procurement teams need, pre-assembled.
- Nationwide delivery footprint — every metro and tier-2 city in India, scheduled to your treatment / procedure calendar.
- AERB & CDSCO documentation — import licence, radiation-safety paperwork and RSO briefing pre-assembled for the audit file.
- 40+ years in Indian oncology — long-standing supply relationships with AIIMS, Tata Memorial, and hundreds of tertiary-care centres.
- Single point of accountability — one purchase order, one delivery contact, one after-sales team across the whole product family.
Also supplied by Saxsons Group across India
Reliable I-131 supply for your thyroid therapy unit
Contact Saxsons Group for prescription-specific I-131 supply, AERB documentation and therapy dose planning support across India.